Optimal Timing for Performing Loop Electrosurgical Excision Procedure

Not Applicable

Completed

• Conditions: Cervical Precancerous Lesions
• Interventions: Other: Vaginal bleeding

• Registration Number: NCT03952975
• Lead Sponsor: Erzincan Military Hospital

Brief Summary

Cervical precancerous lesions (cervical intraepithelial neoplasia) are frequently diagnosed and treated in women of reproductive-aged \[1\]. Loop electrosurgical excision procedure (LEEP) is the standard surgical treatment in CIN 2 or 3 \[1\]. This procedure is an inexpensive, easy to learn and provide specimens for pathological examination with the least major surgical morbidity \[2\].

Although LEEP is a safe procedure, complications such as postoperative bleeding have been reported. These haemorrhages make patients anxious, undergo unnecessary follow-ups, additional procedures to stop bleeding and interfere in patients daily activities. Various interventions have been attempted to prevent and/or reduce perioperative and/or postoperative haemorrhage after LEEP including vasopressiın, tranexamic acid, Monsel's solution, or local hemostats (TochoSil or Tisseel), but have failed to show a definite advantage over routine practice \[2-4\].

A hormonal variation during the menstrual cycle is known to affect hemostasis \[5\] and the blood flow of the genital organ \[6,7\]. A systematic review of the literature through PubMed, OvidSP, Google Scholar, and Scopus identified only one previous investigation of menstrual cycle period affect blood loss during the LEEP procedure. The authors showed that women had less perioperative bleeding during the follicular phase than during the luteal phase \[8\]. Two retrospective studies have also demonstrated rhinoplasty and mammoplasty caused more bleeding during the luteal phase and menstruation than during the follicular phase \[9,10\]. In contrast, other retrospective studies have shown no relation between operative blood loss and the menstrual cycle for hysterectomy, myomectomy, and ovarian cystectomy \[11-13\] To answer this clinically relevant question, the investigators performed a randomized study comparing perioperative and postoperative bleeding between patients underwent LEEP procedure during the follicular or luteal phase of the menstrual cycle.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-05-12
• Study First Submitted QC: 2019-05-15
• Study First Posted: 2019-05-16
• Study Start: 2019-05-20
• Primary Completion: 2019-09-18
• Study Completion: 2019-09-18
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-12
• Last Update Posted: 2019-10-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 75

Inclusion Criteria

1. Women was ≥ 21 years old

2. Women was not pregnant

3. Women were not menstruating or menopausal status

4. Women with the normal regular menstrual cycle (defined as an interval between 21 and 35 days and duration between 3 and 10 days)

5. Women had one of the following indications for LEEP procedure

   1. a histology-proven, persistent, low grade squamous intraepithelial lesions (LGSIL),
   2. a histology-proven high-grade squamous intraepithelial lesions (HGSIL),
   3. discrepancies between cytological reports and colposcopic impressions,
   4. investigation for unsatisfactory colposcopy,
   5. micro invasion or adenocarcinoma in situ on cervical punch biopsy

Exclusion Criteria

• Women with cervical or vaginal infection,
• Women with the abnormal menstrual cycle,
• Women taking any medication (or injection) such as oral contraceptives, GnRH agonist, medroxyprogesterone acetate, or anticoagulants
• Women with coagulation defect,
• Women with mental incapacity,
• Women with a history of neurologic deficit,
• Women with previous hysterectomy with removal of the cervix,
• Women with a history of cervical cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
follicular phase group	Vaginal bleeding	The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14). In light of this formula patients were classified into the follicular phase group (defined as \<15 adjusted days, group A).
luteal phase group	Vaginal bleeding	The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14) \[14\]. In light of this formula, patients were classified into the luteal phase group (defined as ≥15 adjusted days, group B).

Primary Outcome Measures

Name	Time	Method
mean early postoperative blood loss	6 hours	Estimated early postoperative blood loss was calculated using the difference in hematocrit values taken after LEEP procedure and 6 hours after procedure, according to the following formula: Estimated Blood Loss = estimated blood volume X (hematocrit 1 - hematocrit 2)/hematocrit 1, where the estimated blood volume in milliliters = woman's weight in kilograms X 85

Secondary Outcome Measures

Name	Time	Method
the rate of late postoperative bleeding	bleeding that occur within four weeks after the home dischard	late postoperative bleeding (defined as bleeding that occur within four weeks after the home dischard, and required hemostatic interventions such as electrocauterization, gause packing, or cervical suturing, excluding menstrual bleeding).
mean intraoperative bleeding	During the LEEP procedure	The volume of intraoperative blood loss was measured by weighing a gauze sponge during the procedure. Because it is important to collect the blood accurately, we used a specially designed operating gauze sponge and an electronic scale to weigh all the material (with a 1-g deviation range). The LEEP procedure was performed ensuring that all blood lost during the procedure was absorbed with gauzes. We took care to clean all the bleeding with gauze obtained during the procedure.

Trial Locations

Locations (1)

Kemal Gungorduk; 🇹🇷 Muğla, Turkey